A synthetic form of the active ingredient in magic mushrooms has cleared an early-phase trial. The drug, Compass Pathways’ COMP360, came through the placebo-controlled phase 1 without setting off any ...
Readers with a keen interest in the decades-long development of psychedelic-assisted therapy could be forgiven for thinking Christmas has come early. Less than a week after the first-ever request for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results